TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19730304
Drug: 0.2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% lidocaine administered through the vacuum-assisted closure tubing into the foam dressing 30 minutes before dressing change
Study: 19730304
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline administered through the vacuum-assisted closure tubing into the foam dressing 30 minutes before dressing change
Study: 12472837
Drug: Placebo (scaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (scaled groups without mechanical treatment)
Study: 2475697
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of anipamil
Study: 2475697
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of anipamil
Study: 2475697
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of anipamil
Study: 781233
Drug: Fenoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoprofen (200 mg to 600 mg every six hours)
Study: 781233
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg to 975 mg every six hours)
Study: 26143615
Drug: Aluminum-adjuvanted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvanted trivalent PPrV (50 μg per antigen)
Study: 26143615
Drug: Aluminum-adjuvanted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvanted trivalent PPrV (10 μg)
Study: 26143615
Drug: Aluminum-adjuvanted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvanted trivalent PPrV (25 μg)
Study: 26143615
Drug: Aluminum-adjuvanted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum-adjuvanted trivalent PPrV (50 μg)
Study: 23300160
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (TIV) plus 7-valent pneumococcal vaccine (PCV7)
Study: 23300160
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (TIV) alone
Study: 23300160
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal vaccine (PCV7) alone
Study: 6804625
Drug: CO2 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 inhalation
Study: 19602608
Drug: Glucose-based solutions
Normalized name: glucose Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-based solutions (GLU)
Study: 17879825
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) at doses of 0.3, 0.625, and 1.25 mg for 3 months each, totaling 9 months of treatment.
Study: 14693584
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus 1 micro g/kg clonidine
Study: 14693584
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus 2 micro g/kg clonidine
Study: 14693584
Drug: bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine plus 0.25, 0.5 micro g/kg clonidine
Study: 12359987
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with nitrendipine (with second- and third-line enalapril and hydrochlorothiazide)
Study: 31152874
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with anti-arrhythmic drugs
Study: 25319932
Drug: Poly-L-lactic acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-L-lactic acid (PLA) filler
Study: 19349547
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D(3) (cholecalciferol) 400 IU and calcium carbonate 1,000 mg daily for 1 year
Study: 31095602
Drug: MRCI-K (Korean
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRCI-K (Korean version of the medication regimen complexity index)
Study: 25951857
Drug: Tofacitinib 2
Normalized name: tofacitinib 22 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 2 mg, 5 mg, or 15 mg, twice daily for 12 weeks
Study: 17373900
Drug: Trastuzumab (humanised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (humanised monoclonal antibody to the HER2 receptor)
Study: 17373900
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and endocrine therapies
Study: 15292325
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily for nine months
Study: 9034949
Drug: Self‐administered, structured,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered, structured, previsit questionnaire combined with a postvisit questionnaire
Study: 9034949
Drug: Interviewer‐administered, semistructured,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interviewer‐administered, semistructured, previsit interview combined with a postvisit questionnaire
Study: 31328432
Drug: Assisted reproductive
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted reproductive technologies (ART) and non-IVF fertility treatments (NIFTs)
Study: 27999970
Drug: Oral 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 30% glucose solution (2 ml/3 kg doses)
Study: 27999970
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.1 mg/kg with 0.05 mg/kg repetition)
Study: 26356162
Drug: Cerebrolysin (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (intravenously in dose 20 ml in 100 ml of physiological solution, 5 days a week, during 4 weeks)
Study: 20488830
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g glucose
Study: 20488830
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g glucose
Study: 16959149
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Group A)
Study: 15040556
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (AQ + SP, AR + SP, AQ + AR)
Study: 8585876
Drug: Amtolmetineguacil 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetineguacil 600 mg by os twice daily for the first two days followed by 600 mg once daily for 19 days (Group A1)
Study: 8585876
Drug: Amtolmetineguacil 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amtolmetineguacil 600 mg twice daily for 21 days (Group A2)
Study: 8585876
Drug: diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 50 mg twice daily by os for 21 days (Group V)
Study: 31076942
Drug: Concentrated fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrated fish oil in combination with evening primrose oil
Study: 25524913
Drug: 10% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Intralipid at 100 mL/h
Study: 17309405
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral therapy (HAART) with at least three effective ARVs from at least two different drug classes
Study: 17309405
Drug: Adherence to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adherence to drug therapy greater than 95%
Study: 17309405
Drug: Monotherapy, two-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy, two-drug combinations, sequential ARVs, drug cycling, and treatment interruptions
Study: 4009919
Drug: Concurrent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent infusion with 20% fat emulsion
Study: 25980923
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of platelet-rich plasma (PRP)
Study: 28878035
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (3 × 500 mg Ca/d)
Study: 28878035
Drug: Low-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose regimen (2 × 500 mg Ca/d)
Study: 23398636
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diet + 6 × 60 ml/day of Pro-Cal (60 ml = 200 kcal + 4 g protein)
Study: 19845100
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (lidocaine 2.5% plus prilocaine 2.5%) applied daily
Study: 19845100
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate 40 mg injection
Study: 16757756
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with porcine small intestine mucosa
Study: 20467596
Drug: No augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmentation (Control)
Study: 15004874
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg qd) for 12 weeks
Study: 9262274
Drug: Physician-administered fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Physician-administered fentanyl
Study: 22994896
Drug: Inhaled anesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthetics
Study: 25319879
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy with defibrillator (CRT-D)
Study: 23336504
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) intervention with Standard Health Care Advice (SHCA)
Study: 18042987
Drug: 500‐microg F/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐microg F/g (NaF) dentifrice
Study: 18042987
Drug: 1,100‐microg F/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,100‐microg F/g dentifrice
Study: 16209659
Drug: Moxonidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.6 mg)
Study: 1390375
Drug: 0.5mg intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg intrathecal morphine with 3 mls of 0.5% intrathecal bupivacine
Study: 30079637
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) + 5000 ppm sodium fluoride (GLASER)
Study: 27212226
Drug: Transdiagnostic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic group cognitive behavioral therapy (TGCBT) for anxiety over 12 weeks
Study: 25016974
Drug: Psychodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic Therapy
Study: 22873492
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus clavulanic acid vs Sodium benzoate
Study: 21049208
Drug: Group PK
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group PK (0.15 mg/kg ketamine + 80 ml 0.5% prilocaine)
Study: 21049208
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P (80 ml 0.5% prilocaine)
Study: 15816475
Drug: Interferon alpha-2b/ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha-2b/ribavirin combination therapy
Study: 15816475
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b monotherapy
Study: 11443628
Drug: Infusional cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional cyclophosphamide (187.5 mg/m² per day), doxorubicin (12.5 mg/m² per day), and etoposide (60 mg/m² per day) administered as second-line chemotherapy for 96 hours continuous intravenous infusion.
Study: 8079928
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus amoxycillin (500 mg three times a day for 2 weeks) and metronidazole (250 mg three times a day for 2 weeks)
Study: 8079928
Drug: Cimetidine alone
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine alone (800 mg at night for 4 weeks)
Study: 786681
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine sulphate (0.25, 0.40, 0.75 and 1.50 mg)
Study: 786681
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine methylnitrate (0.08, 0.13 and 0.25 mg)
Study: 30755234
Drug: Carbohydrate supplements
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplements (CHO)
Study: 17590218
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg twice a day)
Study: 17590218
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg once a day)
Study: 14733608
Drug: IVIg plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg plus IFNalpha (400 mg/kg each day for 5 days, then 3 MUI of leucocyte IFNalpha three times a week)
Study: 14733608
Drug: IFNalpha alone
Normalized name: Zenalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNalpha alone (physiological solution followed by leucocyte IFNalpha three times a week for 6 months)
Study: 11669086
Drug: Olanzapine (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (20-40 mg/d)
Study: 1180024
Drug: Non-operated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operated group (conservative treatment)
Study: 31075442
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (2 L in divided doses)
Study: 23575965
Drug: Pasireotide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (600 μg or 900 μg) subcutaneously twice daily for 3 months
Study: 23575965
Drug: CushingQOL questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: CushingQOL questionnaire self-administered at baseline, month 3, month 6, and month 12
Study: 15372361
Drug: Metformin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (750 mg/day) for 6 months
Study: 9347208
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 micrograms self-administered vaginally 3 days after methotrexate
Study: 9347208
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 micrograms self-administered vaginally 4 days after methotrexate
Study: 9347208
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 micrograms self-administered vaginally 5 days after methotrexate
Study: 2285656
Drug: Ketanserin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin, 40 mg twice daily for 1 week
Study: 22660805
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg biweekly (twice monthly)
Study: 22660805
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg monthly (alternating with placebo)
Study: 18832341
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (0.16 mJ/mm(2); 2000 impulses)
Study: 16027282
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with or without concurrent chemotherapy
Study: 8624220
Drug: Citicoline 1000
Normalized name: citicoline 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 1000 mg/d for 3 months
Study: 8624220
Drug: Citicoline 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 2000 mg/d for 2 months
Study: 22853197
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (eight-week, step down program) dispensed at discharge
Study: 22853197
Drug: Combined interventions
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined interventions (nicotine patches and telephone counseling)
Study: 22853197
Drug: All interventions
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All interventions (patch alone, counseling alone, and combined interventions)
Study: 18832497
Drug: Second-generation antidepressants
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antidepressants
Study: 17377748
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.2 mg/ml applied to the osteotomy site for 30 min
Study: 12077687
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d enalapril
Study: 9445316
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 250,000 IU intrapleural streptokinase (IPSK)
Study: 9445316
Drug: Serial doses
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serial doses of 250,000 IU intrapleural streptokinase (IPSK) every 12 hours for 3 days (total dose: 1.5 million IU)
Study: 8711268
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg per os 1 h before exercise
Study: 2315637
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (Buscopan) 20 mg i.v.
Study: 2315637
Drug: Glucagon 1
Normalized name: GLUCAGON 1MG/VI INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon 1 mg i.v.
Study: 7401741
Drug: Oxovinca; administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxovinca; administered over three consecutive courses within a two-month period.
Study: 7401741
Drug: Placebo; administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; administered over three consecutive courses within a two-month period.
Study: 27477804
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate (CS) 1,200 mg plus glucosamine sulfate (GS) 1,500 mg
Study: 26055360
Drug: RG7667 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7667 (1, 3, 5, and 10 mg/kg each antibody; single ascending dose)
Study: 26055360
Drug: RG7667 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7667 (5 and 10 mg/kg each antibody monthly for 3 doses; multiple ascending dose)
Study: 26055360
Drug: RG7667 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7667 (10 mg/kg each antibody monthly for 3 doses; multiple dose expansion)
Study: 23857311
Drug: Doxazosin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (8 mg/d)
Study: 16728222
Drug: Rosuvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5 to 40 mg)
Study: 9863080
Drug: Composite Divitriol
Normalized name: DRESSING,COMPOSITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Divitriol Infusion (CDI)
Study: 7945476
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) - transdermal estradiol (50 micrograms daily)
Study: 7945476
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (400 mg daily)
Study: 7945476
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) in patients taking steroids
Study: 3555580
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg quinine bisulphate at night
Study: 3555580
Drug: Increased nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased nightly dose of quinine
Study: 24951828
Drug: Bivalent intramuscular
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent intramuscular norovirus virus-like particle vaccine (50 µg of each VLP)
Study: 18192704
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol 0.75 mcg three times weekly for six weeks
Study: 18192704
Drug: Oral alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alfacalcidol 0.75 mcg three times weekly for six weeks
Study: 15983453
Drug: Liberal protocol
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal protocol group (LPG) - bolus of 10 ml/kg followed by 12 ml x kg(‐1) x h(‐1)
Study: 15983453
Drug: Restrictive protocol
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive protocol group (RPG) - 4 ml x kg(‐1) x h(‐1)
Study: 12028259
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg oral cyanocobalamin
Study: 12028259
Drug: 10 microg
Normalized name: Estradiol 10 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 microg oral cyanocobalamin
Study: 2028626
Drug: Actisomide 4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actisomide 4.2 mg/kg